Abbott Laboratories (ABT) Holdings Lifted by Windsor Capital Management LLC
Windsor Capital Management LLC boosted its holdings in Abbott Laboratories (NYSE:ABT) by 0.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,733 shares of the healthcare product maker’s stock after buying an additional 4 shares during the period. Windsor Capital Management LLC’s holdings in Abbott Laboratories were worth $375,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of ABT. Winfield Associates Inc. grew its holdings in shares of Abbott Laboratories by 3.9% during the 2nd quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock worth $116,000 after purchasing an additional 89 shares in the last quarter. V Wealth Management LLC acquired a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $127,000. JFS Wealth Advisors LLC grew its holdings in shares of Abbott Laboratories by 349.0% during the 2nd quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock worth $131,000 after purchasing an additional 2,094 shares in the last quarter. Burt Wealth Advisors grew its holdings in shares of Abbott Laboratories by 14.4% during the 2nd quarter. Burt Wealth Advisors now owns 3,181 shares of the healthcare product maker’s stock worth $154,000 after purchasing an additional 400 shares in the last quarter. Finally, Farmers National Bank grew its holdings in shares of Abbott Laboratories by 1.5% during the 1st quarter. Farmers National Bank now owns 3,568 shares of the healthcare product maker’s stock worth $158,000 after purchasing an additional 52 shares in the last quarter. 70.64% of the stock is currently owned by institutional investors.
Several analysts have recently weighed in on ABT shares. Zacks Investment Research lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. J P Morgan Chase & Co started coverage on Abbott Laboratories in a report on Friday, October 6th. They set a “neutral” rating and a $60.00 price objective on the stock. Royal Bank Of Canada reissued a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a report on Tuesday, October 3rd. Cowen and Company set a $68.00 price objective on Abbott Laboratories and gave the stock a “buy” rating in a report on Thursday, October 19th. Finally, Barclays PLC reissued an “overweight” rating and set a $57.00 price objective (up previously from $52.00) on shares of Abbott Laboratories in a report on Saturday, July 22nd. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Abbott Laboratories presently has an average rating of “Buy” and an average target price of $56.81.
In other news, insider Stephen R. Fussell sold 196,550 shares of the business’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the completion of the sale, the insider now owns 221,488 shares in the company, valued at $10,963,656. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the business’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $56.21, for a total value of $5,430,054.63. Following the sale, the executive vice president now owns 142,082 shares of the company’s stock, valued at approximately $7,986,429.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 408,313 shares of company stock valued at $21,205,356. Corporate insiders own 0.76% of the company’s stock.
Abbott Laboratories (NYSE ABT) opened at $55.30 on Tuesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $56.69. The stock has a market capitalization of $95,384.93, a price-to-earnings ratio of 22.74, a price-to-earnings-growth ratio of 2.05 and a beta of 1.06.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The firm had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. During the same quarter in the previous year, the company posted $0.59 EPS. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. equities research analysts expect that Abbott Laboratories will post 2.5 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a $0.265 dividend. The ex-dividend date is Thursday, October 12th. This represents a $1.06 annualized dividend and a yield of 1.92%. Abbott Laboratories’s payout ratio is 83.47%.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.